Simufilam is an AD drug candidate that disrupts an upstream pathogenic pathway that hyperphosphorylates tau, prior to the aggregation and deposition of tau or amyloid, as well as a separate neuroinflammatory pathway (Wang et al., 2012; Burns and Wang, 2017; Wang et al., 2017; Wang et al., 2020; Burns et al., 2023). This evidence concerns the gene MAPT and Alzheimer disease.